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Objective: Clinical pathways translate best available evidence into practice, indicating the most widely
applicable order of treatment interventions for particular treatment goals. We propose a practice-
based clinical pathway development process and a data-driven methodology for extracting common
clinical pathways from electronic health record (EHR) data that is patient-centered, consistent with
clinical workflow, and facilitates evidence-based care.
Materials and methods: Visit data of 1,576 chronic kidney disease (CKD) patients who developed acute
kidney injury (AKI) from 2009 to 2013 are extracted from the EHR. We model each patient’s multi-
dimensional clinical records into one-dimensional sequences using novel constructs designed to capture
information on each visit’s purpose, procedures, medications and diagnoses. Analysis and clustering on
visit sequences identify distinct types of patient subgroups. Characterizing visit sequences as Markov
chains, significant transitions are extracted and visualized into clinical pathways across subgroups.
Results: We identified 31 patient subgroups whose extracted clinical pathways provide insights on how
patients’ conditions and medication prescriptions may progress over time. We identify pathways that
show typical disease progression, practices that are consistent with guidelines, and sustainable improve-
ments in patients’ health conditions. Visualization of pathways depicts the likelihood and direction of
disease progression under varied contexts.
Discussion and conclusions: Accuracy of EHR data and diversity in patients’ conditions and practice
patterns are critical challenges in learning insightful practice-based clinical pathways. Learning and
visualizing clinical pathways from actual practice data captured in the EHR may facilitate efficient prac-
tice review by healthcare providers and support patient engagement in shared decision making.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Evidence-based medicine is widely acknowledged as a system-
atic approach for delivering consistent, credible, and safe health-
care [1]. It is a critical assumption in the Affordable Care Act of
2010 to achieve coordinated, patient-centered, and effective
healthcare [2]. However, validated models, methods and tools
required to apply evidence-based medicine at the point of care,
particularly those that accommodate insights from current prac-
tice, are lacking. An important source for medical evidence is clin-
ical pathways, indicating the most widely applicable order of
treatment interventions for particular patient groups [3]. Clinicalpathways translate best available evidence into practice, are
known to reduce in-hospital complications, and reduce length of
stay and medical expenses [3]. In the US, more than 80% of the
hospitals use clinical pathways for at least one intervention [4].
Clinical pathways are developed based on clinical practice
guidelines (CPGs), which list recommendations for various treat-
ments based on evidence from randomized clinical trials (RCTs).
However, the strength of such evidence differs by clinical areas.
For example, while recommendations in CPGs for conditions such
as hypertension are frequently based on consistent and good
quality patient-oriented evidence [5], those for chronic kidney
disease (CKD) are known to be mostly consensus-based due to
the difficulties in patient recruitment and high cost of RCTs [6].
Hence, CPGs often face concerns about oversimplification, inade-
quate applicability to the average patient, and resistance from
practicing physicians [7,8].
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records (EHRs), gain widespread adoption and use in healthcare
industry, thereby accumulating vast amounts of real-time patient
care data, there is tremendous opportunity to develop data-
driven models, methods and tools to facilitate review of practice
workflows and improve evidence-based care delivery by learning
practice-based pathways of care [7]. In this study, we aim to lever-
age this opportunity using a ‘paving the COWpaths’ approach [9],
where ‘COWpaths’ refer to the most common clinical ‘paths’ or
treatment patterns followed by patients, and oftentimes recorded
using ‘computer on wheels’ (COW), and identified via retrospective
analysis of patients’ EHR data. They reflect the multitude of day-to-
day clinical decisions made by many clinicians across many
patients over a significant duration, and is an important and effec-
tive first step in managing change resulting from technological
innovation. Upon thorough evaluation and validation by medical
experts, we anticipate that these ‘COWpaths’ may be utilized as
‘practice-based clinical pathways’, to overcome the challenges
faced by current CPGs, and also serve as individualized treatment
guidelines.
In this paper, we aim to learn practice-based clinical pathways
for chronic kidney disease (CKD), a chronic condition where
patients gradually lose their kidney’s functions, progressing from
stage 1 to stage 5, and end stage renal disease (ESRD) [10]. It is a
costly, complex and high mortality health condition affecting
26 million US adults, with another 73 million at increased risk for
the disease [11]. In 2011, CKD patients above 65 years old made
up 9.2% of US Medicare population (2.3 million), but incurred
18.2% of Medicare costs ($45.5 billion) [12]. Typically, the manage-
ment of CKD is focused on delaying the progression of the
condition, such as maintaining patients in their current disease
stage and delaying the progression from stage 5 to dialysis [13].
Two widely known CPGs for CKD are Kidney Disease Outcomes
Quality Initiative (KDOQI) and Kidney Disease: Improving Global
Outcomes (KDIGO), which summarize global CPGs for various com-
plications of kidney disease [14,15]. Yet, many recommendations
are consensus-based, or based on evidence from small-scale
randomized clinical trials (RCTs) [14,15]. Recent studies suggest
that care delivery changes in CKD management may improve
clinical outcomes, enhance quality of patient experience, and
reduce annual total per capita health spending [16]. This is of
critical importance in the special case of CKD patients who have
developed acute kidney injury (AKI) whose consequences are
serious and even fatal at times. Yet, few standard preventive and
therapeutic options exist for AKI, and there is a growing movement
among nephrologists to develop a CPG for AKI [6]. In this study, we
specifically focus on AKI as a likely condition that can benefit from
insights provided by practice-based clinical pathways that may be
learned from EHR data.
We propose a practice-based clinical pathway development
process, shown in Fig. 1, that integrates health IT and domain
knowledge, including representation of multidimensional and
longitudinal EHR data, identification of distinct patient subgroups,
and extraction of common treatment patterns as candidate clinical
pathways that constitute the focus of this paper. Subsequently,Fig. 1. Practice-based clinical patmedical experts need to evaluate candidate clinical pathways
and their outcomes, and make modifications and redesign, when
necessary, to complete the process. Furthermore, we provide
visualizations of the learned pathways that can be used by health-
care providers for practice review and decision support, and by
patients to engage in shared-decision making, communication,
and education. This paper is organized as follows. In Section 2
we describe the data representation, clinical pathway extraction
methods, as well as our study data. Analytical results and evalua-
tion are presented in Section 3. We discuss limitations and future
work in Section 4 and Section 5 concludes the paper.
2. Materials and methods
2.1. Related work
Previous studies have identified clinical pathways and care
patterns from EHR using statistical models, process mining, and
machine learning [17–21]. Among studies that used statistical
models, Lin et al. and Poelmans et al. modeled clinical pathways
as a hidden Markov model (HMM), a stochastic model for ran-
domly changing processes, that includes sequences of hidden
states and observations [22,23]. Hidden states in the HMM are
assumed to be states in the clinical pathway, and observations
are actual interventions that occurred in practice. Generally, a large
amount of data is necessary to train a HMM. On the other hand,
process mining approaches take process logs as inputs, and in
the case of clinical pathway mining, clinical activities recorded in
EHR are used as process logs [20]. Many of the process mining
approaches, such as Heuristic Miner and Fuzzy Miner, assume that
event logs contain sufficient information and minor noise [24,25].
This assumption leads to spaghetti-like workflow models that are
hard to interpret, as diversity is innate to most of the health data
[19]. Recently, while still a process mining approach, Huang et al.
presented sequence mining algorithms for clinical pathway
patterns that did not look for an entire clinical pathway from start
to end, but rather patterns of clinical pathways including time dif-
ferences between events [21]. Also, machine learning techniques
provide a potential solution to spaghetti-like workflow models
by segmenting patients into relatively homogeneous groups before
learning clinical pathways [18,26,27]. For example, Greco et al.
used hierarchical clustering to cluster patients’ sequences of visits
[27], and Lakshmanan et al. segmented patients by their outcomes,
followed by further clustering using DBScan and frequent pattern
mining using SPAM [18].
Models from these studies have primarily been applied to
clinical processes where each point in the pathway is a clinical
event that bears, or is assumed to bear, clear temporal relationship
with another [19,21]. However, in the outpatient setting especially,
time stamps associated with clinical activities are typically per day
[18]. Such lack of accurate temporal ordering presents a mining
challenge for previous methods to accurately learn the co-
progression of interventions and outcomes. For example, CKD
patients visit clinics and hospitals every few months depending
on the severity of their conditions. During each visit, theyhway development process.
Table 2
Transformation using nodes.
Patient Date Purpose Procedure Medication Diagnosis
1 3/1/12 Education N/A M1 D1
1 7/1/12 Office P1 M2 D2
1 12/1/12 Office N/A M2 D1
1 2/1/13 Hospital N/A M3 D3
Table 3
EHR extract illustrating modeling elements, post-data transformation.
Patient Visit date Super node
1 3/1/12 V3
1 7/1/12 V1
1 12/1/12 V5
1 2/1/13 V2
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dures and medication prescriptions. Table 1 is a sample summary
of EHR data associated with a patient’s visits. As the table shows,
no clear temporal relationship exists between each clinical activity
in the EHR data within one visit, because their time stamps are all
on the same day. Furthermore, patients with chronic conditions
commonly suffer from multiple comorbidities [12], resulting in
multiple diagnoses noted and medications prescribed during
a visit. To solve this challenge, we propose a novel data
representation method to enable frequent pattern mining on such
multidimensional and longitudinal treatment data. Furthermore,
we expect our clinical pathway learning algorithm to be consistent
with clinicians’ decision process, and allow it to adapt to different
levels of data complexity, to enable the efficient learning of
interpretable clinical pathways.
2.2. Data transformation
In this paper, we consider each visit as a point in the clinical
pathway, and track the co-progression of interventions and out-
comes over time. Below we illustrate the data representation steps
to establish correct temporal relationships among multiple clinical
events of different types.
Def 1. elk, k = 1, . . ., Kl, l = 1,. . ., L, represents a set of Kl events of L
specific types, referred to as ‘node’ hereafter, that occurs during a
patient’s medical visit.
In Table 1, ‘Office’ event is of encounter type, ‘CKD Stage 3’
event of diagnosis type, ‘Diuretics’ event of medication type, and
‘Renal ultrasound’ of procedure type.
For example, in Table 1 patient 1’s record can be transformed
using node as below in Table 2. Procedure, medication, and
diagnosis nodes are named as Pj, Mj, and Dj, respectively, j 2 Zþ.
The numbering of the nodes only serves to distinguish nodes, and
does not represent any temporal ordering. Medications from
7/1/12 and 12/1/12 are represented as ‘M2’ because the items
contained in these 3 nodes are identical: {ACE inhibitors, diuretics}.
Our goal is to identify common sequences from the data that
can constitute as clinical pathways. To do so efficiently, we
introduce a modeling element called super node to represent
unique visit content. Each super node captures a unique combina-
tion of visit purpose, procedure, medication and diagnosis. Super
nodes collapse multi-dimensional records of visit such that they
can be represented as a sequence of visits (super nodes) ordered by
visit dates. Each patient has one and only one sequence, starting
with the first visit recorded in the EHR and ending with the last
visit.Def 2 (Super node (SN)). Event sequence V is a set of supernodes
{V1, V2, . . ., VK}, where each node Vi is a nonempty subset of elk,
where K = all possible combinations of K1, K2, K3 and K4. Each visit
of each patient can be represented as an element of the event
sequence. Visits are ordered chronologically such that nth visit
occurs before (n+1)st visit.Table 1
EHR summary, pre-data transformation.
Patient Visit date Description of visit
Visit purpose Procedure
1 3/1/12 Education N/A
1 7/1/12 Office Renal ultrasound
1 12/1/12 Office N/A
1 2/1/13 Hospital N/A
a Angiotensin converting enzyme.For example, patient 1’s record can be transformed using super
nodes as shown in Table 3. Each super node is labeled as Vj, j 2 Zþ.
Similar to nodes, the numbering of each super node only distin-
guishes one super node from another and does not represent its
chronological occurrence in the sequence.Def 3 (Visit sequence). The nth visit of patient p, p = 1, . . .P, with Np
visits, can be represented as
VisitpnfVig; i ¼ 1; . . .K; n ¼ 1; . . .Np
For example, in Table 1, Visit11 = {Education, CKD Stage 4, hyperten-
sion, ACE inhibitors} 2 {Vi}, i = 1, . . ., K, and Visit12 = {Office, renal
ultrasound, AKI, CKD Stage 4, Hypertension, ACE inhibitors} 2 {Vi},
i = 1, . . ., K. Hence, patient p’s visit sequence can be represented as:
Qp = {Visitpn}, n = 1, . . ., Np, where Visitpn 2 {Vi}, i = 1, . . ., K, and
|Qp| = Np. For example, Q1 = {V3, V1, V5, V2}, where patient 1 has 4
visits.2.3. Identification of patient subgroups
We expect considerable diversity across patients undergoing
various interventions. Hence, prior to clinical pathway extraction,
we cluster patients’ sequences of visits into subgroups such that
we can extract clinical pathways for distinct types of patients.
Since each patient has one and only one sequence, this is essen-
tially the same as clustering of patients. To measure similarity
among sequences, we use longest common subsequence (LCS),
the maximum number of items that 2 sequences have in common,
while preserving the order of occurrence but possibly separated
[28].
LCSðx; yÞ ¼ maxfjuj : u 2 Sðx; yÞg
where |u| is the length of the common subsequence for the pair of
sequences (x, y), and S(x, y) is the nonempty set of common subse-
quences of sequences x and y. A distance measure based on LCS is
defined as:Medication Diagnosis
ACEa inhibitors CKD stage 4, hypertension
ACE inhibitors, diuretics AKI, CKD stage 4, hypertension
ACE inhibitors, diuretics CKD stage 4, hypertension
ACE inhibitors, diuretics, statins AKI, CKD stage 5, hypertension
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where |x| is the length of sequence x and |y| is the length of
sequence y. Comparison of each pair of visit sequences generates
a dLCS based distance matrix for the entire sample of patients. For
example, 100 visit sequences will yield a 100 by 100 distance
matrix of dLCS. Since patients’ clinical pathways follow clinical
decisions made at each visit that is dependent on earlier decisions,
we expect recurrent splittings of patient population [29], resulting
in a hierarchical data structure. Hence, we use hierarchical cluster-
ing, a well-known cluster analysis technique that has been applied
to biomedical data analysis extensively [30–32], with the dLCS
matrix, to cluster patients into subgroups.
2.4. Clinical pathway extraction
Whenmaking treatment plans during a visit, clinicians from our
study site report that they commonly review 2 previous visit
records. Our clinical pathway extraction algorithm mimics this
decision making process for CKD management [26,33], and models
patients’ visit sequences as discrete, time homogeneous Markov
chains. Markov chains exhibit memoryless property; for example,
in a first-order Markov chain the current state only depends on
the previous state:
PðXt ¼ YjjXt1 ¼ Yi;Xt2 ¼ Yk; . . . ;X1 ¼ YlÞ ¼ PðXt ¼ YjjXt1 ¼ YiÞ
The assumption of memoryless property in representing
sequential clinical workflow has been used in Meier et al. [34],
Vankipuram et al. [35], Bouarfa et al. [36], and Li et al. [37]. In addi-
tion, we assume time-homogeneity, such that (Xs+t = Yj|Xs = Yi) is
independent of s. Time-homogeneity gives rise to a state transition
probability distribution, which is denoted as A = {aij} where
aij ¼ PðXtþ1 ¼ YjjXt ¼ Yig;1  i; j  N;aij  0, and
PN
j¼1aij ¼ 1.
Through the Markov model process, we want to represent a clinical
practice that each treatment decision from a patient’s visit is
dependent on information from 2 previous visits. Below we show
the modeling process and define super pairs SP as the state ele-
ments of the Markov chain.
Def 4 (Super pair (SP)). A superpair VVm = {Vi, Vj}, i– j, i, j = 1, . . ., K
consolidates pairs of supernodes into a single superpair node.
In the above example, patient 1’s visit sequence will transform
from {V3, V1, V5, V2} to form a Markov chain of {VV1, VV4, VV3},
where VV1 represents transition from V3 to V1, VV4 represents
transition from V1 to V5, and VV3 represents transition from V5
to V2. In this Markov chain, the occurrence of VV4 depends only
on VV1, and VV3 depends only on VV4. In terms of actual visits,
this means that V5 depends on V3 and V1, and V2 depends on
V1 and V5, as in the clinicians’ practices. Fig. 2 summarizes the
transformation of EHR data elements to generate Markov chains.
The transition matrix of Markov chain includes all transitions
from all patients’ visit sequences of super pairs within each
subgroup. Clinical pathways are built by connecting transitions of
super pairs in the Markov chain that are above a desirable thresh-
old in probability, minPr, and frequency, minC, such that we
capture significant transitions in the patient population. A pseu-
docode of the algorithm is shown in Fig. 3.
To illustrate the algorithm, Fig. 4 shows a 5 by 5 transition
matrix from a Markov chain. We can observe the transition proba-
bility, Pij, and transition frequency, Cij, of each transition, where i,
j = 1–5. If we set the threshold for transition probability to be 0.3
and frequency to 3, then we have 2 pathways: VV1–VV2–VV4–V
V3–VV5–VV2 (in green arrows), and VV1–VV2–VV3–VV5–VV2
(in blue arrows). Alternatively, if the threshold is raised to 0.5 for
probability and 4 for frequency, the extracted pathway is narroweddown to VV1–VV2–VV4–VV3–VV5 (in orange arrows). In our
analysis, the thresholds are determined to facilitate clinical
interpretation.2.5. Study data
EHR extract of 1,576 CKD patients from 1/1/2009 to 6/30/2013
was obtained from a community nephrology practice in Western
Pennsylvania. All patients had at least one instance of AKI (ICD9
code = ‘584.xx’ or doubling of creatinine [38]), and at least 5 visits.
There are 726 female patients and 850 male patients in the dataset.
Caucasian, African american, and other races make up 90%, 7%, and
3% of the study patients, respectively. Patients are categorized by
age; 70%, 25%, and 5% of the patients are 70 years and older,
between 50 and 70 years, and below 50 years old, respectively. A
total of 407 patients are reported to have deceased during the
study period, but this may be an underestimate due to loss to
follow up. Table 3 lists the clinical components studied in the
paper. Visit purpose is categorized into office, hospital and CKD
education visits. We include in this study only the major
conditions suffered by CKD patients: CKD stage 1 to stage 5, AKI,
hypertension, diabetes, end stage renal disease (ESRD); and top 4
common drug classes: Angiotensin converting enzyme (ACE) inhi-
bitors, Angiotensin receptor blockers (ARB), diuretics, and statins.
According to KDOQI guideline on blood pressure [14], there are
few RCTs that have compared the use of ACE against ARB, as well
as ACE/ARB combined with diuretics, so the potential to generate
new insights regarding the use of these medications motivated
their inclusion in our analysis. All procedures specified using
Current Procedural Terminology (CPT) codes in the data are
included in the pathway analysis [39]. Given the number of visit
types, procedures, diagnoses and medications, the total possible
number of super nodes is 3,276.3. Evaluation
3.1. Data transformation
A total of 17,358 visits are included in the dataset. Table 4 lists
the percentage of each visit purpose, diagnosis and drug class in
the data, and in the super nodes representing unique combinations
of visit contents. Our analysis found limited number of procedures
in the data so we omit them in the table. A total of 804 super nodes
were generated from the data. Fig. 5 shows the distribution of
super nodes, whose shape exhibits a power law distribution [40].
Roughly 80% of the observations are accounted for by the top
20% of the super nodes, in accordance with the Pareto principle
[41].
The common diagnoses and medications in this patient popula-
tion across all visits are also indicated in the table. For example,
83.9% of patients are, or were at some point, in CKD stage 3, and
CKD stage 3 was noted as a diagnosis in 45.4% of the visits. The
table also reveals the diversity level that each pathway component,
such as a diagnosis, contributes by displaying its percentage in the
set of all unique super nodes. Relatively low percentage in the
super node set suggests that the pathway component occurs with
a relatively stable group of components such that their combina-
tion maps into the same super node, whereas relatively high per-
centage suggests that the component tends to occur with varying
groups of other components, resulting in larger variability. For
example, hypertension is present in only 10.4% of the unique set
of super nodes, though clinicians marked hypertension as a diag-
nosis in 97.7% of the visits. On the other hand, ARB shows up in
36.9% of the super node sets, while it was part of the prescription
in only 26.5% of the visits.
Fig. 2. Modeling visit history as Markov chain.
Fig. 3. Pseudocode of the clinical pathway extraction algorithm.
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Cluster analysis identified 31 patient subgroups from the data
on 1,576 patients. Table 5 lists summary statistics and the most
frequent visit content across subgroups. No procedures were
among the most frequent visit contents, so we omit it from the
table. We calculated the support for the most frequent visit contentusing Sequential Pattern Discovery using Equivalence classes
(SPADE), a type of frequent sequence mining technique [42]. Sup-
port indicates the percentage of patients who experienced the
specific visit at least once in their visit sequences, and therefore
high support reflects similarity among patients’ visit sequences.
Broadly, subgroups separate by diagnoses, then further by the
combination of medication prescription. Support values across
Fig. 4. Extraction of clinical pathways using Markov chain transition matrix.
Table 4
Summary statistics of visit purpose, diagnosis and drug class.
Description % Patients affected
(out of 1576)
% in visits (out
of 17,358)
% in all unique SNs
(out of 804)
Visit purpose
Office 98.4 62.3 49.5
Hospital 82.3 35.3 42.3
Education 19.8 2.4 8.2
Diagnosis
CKD stage 1 2.3 0.5 3.9
CKD stage 2 14.1 3.7 12.9
CKD stage 3 83.9 45.4 27.5
CKD stage 4 63.7 35.7 28.5
CKD stage 5 15.6 4.6 14.2
AKI 100.0 28.3 38.6
Hypertension 97.0 97.7 10.4
Diabetes 51.1 54.5 3.9
ESRD 16.9 8.5 12.9
Drug class
ACE inhibitors 42.0 31.5 40.5
ARB 33.8 26.5 36.9
Diuretics 69.9 63.5 56.7
Statins 63.4 60.5 52.5
Fig. 5. Distributions
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where no commonality was found in terms of visit content among
patients.
3.3. Extracted clinical pathways
Clinical pathway extraction and visualization was performed
for all subgroups to identify common pathways of disease progres-
sion and treatment. Fig. 6 displays the time to extract clinical path-
ways across subgroups in seconds, from the longest to shortest.
While most pathways depict expected progression patterns, such
as progression of CKD via development of AKI, others contained
insightful information such as the potential association of educa-
tion sessions with improvement, which needs further investigation
using larger sample of patients. The state space of the Markov
chain contains 3,505 super pairs. We illustrate the clinical pathway
extraction and visualization step after subgroup clustering using
two examples below.
Fig. 7 plots clinical pathways extracted from all 14 patients’
sequences in subgroup 29, where most patients are in CKD stage
4 and hypertensive and take ACE inhibitors and statins. Each node
represents a super pair, and the edges represent the transitionsof super nodes.
Table 5
Summary statistics across patient subgroups.
Sub group # Patients Visit content with the highest support
Purpose Diagnoses Drug Class Support
1 80 Office CKD stage 3, diabetes, hypertension – 0.54
2 16 ACE 1
3 55 ACE, ARB, diuretics, statins 0.78
4 122 ACE, diuretics, statins 0.7
5 21 ACE, statins 1
6 10 ARB 1
7 36 ARB, diuretics 0.75
8 22 ARB, statins 0.95
9 74 Diuretics 0.69
10 83 Diuretics, statins 0.84
11 75 Statins 0.63
12 158 CKD stage 3, hypertension – 0.52
13 29 ACE 0.72
14 66 ACE, diuretics, statins 0.77
15 14 ACE, ARB, diuretics 0.86
16 32 ACE, diuretics 0.69
17 26 ACE, statins 0.96
18 14 ARB 0.93
19 19 ARB, diuretics 0.95
20 20 ARB, statins 0.95
21 86 Diuretics 0.57
22 100 Diuretics, statins 0.59
23 68 Statins 0.71
24 90 CKD stage 3/4, diabetes, hypertension ARB, diuretics, statins 0.67
25 38 CKD stage 3/4, hypertension ARB, diuretics, statins 0.6
26 18 CKD stage 4, diabetes, hypertension ACE, diuretics 0.67
27 14 ACE, statins 1
28 69 Diuretics, statins 0.94
29 14 CKD stage 4, hypertension ACE, statins 1
30 29 Hospital AKI, CKD stage 3 – 0.55
31 78 Deceased 0.15
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shown by its relative size, and the thickness of the edges repre-
sents frequency of connections. The threshold for minPr is 0.1
and for minC is 1, and the average length of the sub-pathway is
4.3. Fig. 8 expands the sub-pathway made up of red nodes, which
is one of the most dominant patterns seen in subgroup 29. Out of
the 14 patients in subgroup 29, 11 patients experience at least a
part of this sub-pathway. This sub-pathway illustrates a process
of patients repeating office visits and education sessions to prepare
for progression to ESRD. Patients later experienced AKI-related
hospitalizations, which led their conditions to worsen to ESRD,
and subsequently passed away. These patients were on ACE inhibi-
tors and statins throughout the pathway duration. The KDOQI
guideline for CKD recommends ACE inhibitors for lowering blood
pressure [14].
Fig. 9 displays clinical pathways from subgroup 4 of 122 CKD
stage 3, diabetic and hypertensive patients taking ACE inhibitors,
diuretics and statins. The threshold for minPr is 0.05 and for minC
is 2, and the average path length is 4.4. Out of the 122 patients,
72 patients experienced at least a subset of the activities in theseFig. 6. Time to extractclinical pathways. A sub-pathway made up of red nodes is charac-
terized by consecutive hospitalizations leading eventually to the
demise of these patients. Fig. 10 displays the expansion of this
sub-pathway, of which 36 patients experience at least a part.
Another sub-pathway, in Fig. 11, shows that even though CKD
patients rarely improve, patients showed improvement from
CKD stage 4 to CKD stage 3, and receiving education sessions on
CKD may have potentially contributed to such improvement.
Fifty-four patients experience at least a part of this sub-pathway.
In both sub-pathways, a diuretic was given to patients along with
ACE inhibitors. The KDOQI guideline recommends combined use of
both medications to increase patient adherence[14]. Further inves-
tigation of these patients’ life style choices, health conditions, and
medication usage may identify treatments that help patients
achieve and maintain improvements in their health conditions.
3.4. Comparison against an existing method
We evaluate our algorithm against Heuristics Miner [25] from
ProM [43] using subgroup 29. Clinical pathways generated by ourclinical pathways.
Fig. 7. Clinical pathway mined for subgroup 29.
Fig. 8. Visualization of a clinical pathway for patients in subgroup 29. Yellow node: office visit, green node: hospitalization, blue: education visit, red: deceased, CKD4: CKD
stage 4, HP: hypertension. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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tively. The number in the boxes in Fig. 12 is the number of times
that each item appeared in the EHR, and the numbers on the edges
are the number of times the transitions took place [25,44]. The
major advantage of our algorithm over Heuristics Miner is the abil-
ity to show the correct temporal associations and informationencoding. For example, dependencies identified using Heuristics
Miner suggest associations such as ‘‘prescription of statins pre-
cedes hospitalization” that are imprecise and distracting for deci-
sion makers. A more appropriate association should be that an
office visit that includes diagnoses of CKD stage 3 and hypertension
and prescription of statins is followed by a hospital visit, and so on,
Fig. 9. Clinical pathway mined for subgroup 4.
Fig. 10. Visualization of a sub-pathway for patients in subgroup 4. Yellow node: office visit, green node: hospitalization, red: deceased, C2/3: CKD stage 2/3, DH: diabetes and
hypertension, DS: diuretics and statins. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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tage of our algorithm is its depiction of pathways with realistic
complexity and associations. Fig. 12 presents an overly simplified
process, which is rare in healthcare settings. On the other hand,
our algorithm ensures that each visit in the clinical pathway is
dependent on previous 2 visits by using super pairs and Markov
chains, to reflect the actual decision making process in disease
management. For example, we can elicit sub-pathways, such as
Fig. 8, from the complete clinical pathway in Fig. 7, that present
a comprehensive association between visits.4. Discussion
4.1. Implications
The implications of learning clinical pathways from data can be
two-fold. Healthcare providers can utilize them to compare local
practice against consensus guidelines, and to identify common
practice patterns, promising care delivery pathways, and
unwanted care variations. The data representation method pre-
sented in this paper allows efficient comparison among patients’
Fig. 12. Clinical pathway mined using Heuristic Miner in subgroup 29.
Fig. 11. Visualization of a sub-pathway for patients in subgroup 4. Yellow node: office visit, green node: hospitalization, red: deceased, C3/4: CKD stage 3/4, DH: diabetes and
hypertension, DS: diuretics and statins. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Y. Zhang et al. / Journal of Biomedical Informatics 58 (2015) 186–197 195clinical histories and detection of variations in health conditions
and medication usage that are otherwise hard to achieve. Examin-
ing variability in the whole patient sample or by diagnosis or drug
class, and analyzing the resulting clinical pathways, may provide
important insights to healthcare providers about treatment
choices. In addition, learning clinical pathways across practices in
defined geographic regions can also inform better population
health management.
We have demonstrated that patients can be categorized into
subgroups based on their conditions and medications. These are
subject to change as patients continue their visits. Over time,
patients and clinicians can learn about the changing subgroup
assignment and clinical pathways for each patient, determine a
patient’s potential position on a given pathway, and facilitate dis-
cussions about personalized treatment decisions. According to a
2012 report by the Institute of Medicine, patients have consider-
able desire for shared decision making, but there is a significant
gap between expected and actual engagement in the care they
experience [45]. Visualizing practice-based clinical pathways and
personalizing them for individual patients and their clinicians have
the potential to support consistent and effective communication
between patients and their healthcare providers, and improve sat-
isfaction and health outcomes.
4.2. Limitations
Accuracy and completeness of the data is crucial for developing
insightful practice-based clinical pathways. When data is capturedin EHR to meet billing and reimbursement objectives, extensive
time and effort are needed to clean the data and understand the
underlying treatment processes so that clinical pathways mined
from such data can produce meaningful information. For instance,
chronic comorbidities such as hypertension are usually noted only
during patients’ initial visit or when there is a significant change in
disease state, hence tracking and verifying this information at
every visit is a challenge. Similarly, depending on the EHR, some-
times medication information is updated only when a change is
made, and is not always recorded in between. Additionally,
although the entire dataset dates back to 1994, the practice
was using an older version of ICD9 codes for diagnosis until 2009
and did not have separate codes for CKD stages. Missing laboratory
data compounded the problem and hindered manual calculation
of the missing CKD stages. Finally, many of the patients in the
dataset are active patients in the clinics; hence, the pathways
presented here provide only a partial view of their entire clinical
history.
The unique modeling approach for multidimensional data rep-
resentation described in this paper supports efficient pattern
search and provides flexibility in dealing with the diverse patient
information. However, common patterns in patients’ treatment
data that constitute the clinical pathways are identified at the
expense of missing rare events. In addition to learning clinical
pathways, our methods can also be used to identify rare events
of interest in the pattern of treatments, if appropriate patient filter-
ing and selection of probability and frequency thresholds are
applied in the algorithm.
196 Y. Zhang et al. / Journal of Biomedical Informatics 58 (2015) 186–1974.3. Future work
In this study, the number of patients in each subgroup ranged
from 10 to 158. High variability in disease progression, treatments
and day-to-day management was a challenge in identifying inter-
esting pathways supported by large numbers of patients. Larger
patient samples in future studies may allow us to draw more con-
clusive comparisons between practice-based evidence and guide-
line recommendations. Evaluation of the practice-based clinical
pathways developed in this paper is an important next stage.
Analyzing pathways associated with specific outcomes, such as
dialysis or mortality, and segmenting patients who have differing
outcomes can provide useful insights on the effectiveness of treat-
ments and patient management strategies. In terms of methodolo-
gies, the next challenge is the incorporation of additional factors
such as laboratory values in the clinical pathway to predict
patients’ future visit content and develop probable clinical
pathways for each individual. Availability of cost data may further
facilitate the tracking of data-driven clinical and cost pathways
simultaneously, utilizing the methodologies presented in this
paper. These methods can be applied to not only CKD treatment
data, but also to other datasets with similar data components
and structures. Expanding the scalability of the method, such that
it can handle more relevant components, causes and complica-
tions, is an ongoing area of research.5. Conclusion
Developing practice-based clinical pathways has the potential
to positively influence practice review, shared decision making
between patients and healthcare providers, and cost reduction. In
this study, we explored methods to efficiently summarize and
learn clinical pathways from treatment data of 1,576 CKD patients
in the outpatient care delivery environment. Selection of clinical
pathway components was performed based on consultation with
clinicians and existing CPGs with the goal of learning practice-
based evidence from data that can help disambiguate guidelines.
Patients’ multidimensional and longitudinal clinical histories are
represented as one-dimensional sequences of visits, capturing each
visit’s purpose, procedures, medications and diagnoses. We apply
hierarchical clustering with LCS distance measure on patient
sequences to separate patients into 31 distinct subgroups. Further
modeling of visit sequences as Markov chains allows us to identify
and visualize pathways that show typical disease progression,
practices that may be consistent with guidelines, and sustainable
improvements in patients’ health conditions. Our data transforma-
tion and pathway extraction methods are efficient, consistent with
actual clinical practice, and also generalizable to other clinical
areas with similar data structures.Competing Interests Statement
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